Chris Xu
Director
CESCA A Boyalife Company.
China
Biography
Dr. Xu has served on Cesca’s board of directors since March 2016, and was appointed chairman and interim chief executive officer in November 2016. He brings to Cesca over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a China-based diversified life sciences holding company and is currently the principal shareholder of Cesca. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded companies and as a vice president at Founder Group, a Chinese technology conglomerate focused on information technology, pharmaceuticals, real estate, finance, and commodities trading. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).
Research Interest
Clinical Sciences.
